Skip to main content
. 2020 Nov 13;39(4):759–765. doi: 10.1097/HJH.0000000000002708

TABLE 3.

Summary of safety results

Needle type
Umbrella-shaped Single needle Total
N = 25 N = 5 N = 30
Patients with at least one AE [n (%)] 18 (72%) 2 (40%) 20 (66.7%)
Patients with at least one serious AE [n (%)] 5 (20%) 0 (0%) 5 (16.7%)
Patients with at least one RFA-related AE [n (%)] 11 (44%) 0 (0%) 11 (36.7%)
Patients with at least one serious RFA-related AE [n (%)] 2 (8%) 0 (0%) 2 (7%)
Safety-specific secondary outcomes
 Pneumothorax 3 0 3
 Transient post-RFA pain 3 0 3
 Retroperitoneal hematoma 0 0 1
 Infection 0 0 1
Number of RFA-related AEs (n = 14)a
 Pneumothorax 3 0 3
 Transient post-RFA pain 3 0 3
 Dorsalgia 1 0 1
 Renal polar arterial injury 1 0 1
 Chest painc 1 0 1
 Malaise 1 0 1
 Small adjacent hepatic RF injury 1 0 1
 Chronic kidney failureb 1 0 1
 Acute kidney failureb 1 0 1
 Vomiting 1 0 1

RFA, radiofrequency ablation.

a

Fourteen (14) RFA-related adverse events (AE)s in 11 patients.

b

Acute and chronic kidney failure were declared for the same patient.

c

Chest pain was a ‘serious’ event leading to the prolongation of hospitalization.